Form 4: CorMedix CFO Susan Blum's Stock Transactions

CorMedix Inc.'s EVP and CFO, Susan Blum, reported the acquisition of restricted stock units and the disposition of shares for tax withholding purposes.

Summary

• Susan Blum, Executive Vice President and Chief Financial Officer of CorMedix Inc., reported changes in her beneficial ownership of the company's common stock.
• On January 23, 2026, Blum acquired 72,820 shares of common stock, which represent restricted stock units (RSUs) granted at a price of $0.00.
• These restricted stock units vest 1/4 on the grant date, and 1/4 on the first, second, and third anniversaries of the grant date, contingent on continued employment.
• Also on January 23, 2026, Blum disposed of 9,767 shares of common stock at a price of $7.27 per share.
• This disposition was executed for tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Blum directly beneficially owns 132,739 shares of CorMedix Inc. common stock.
• A Power of Attorney was filed, appointing Beth Zelnick Kaufman as attorney-in-fact to handle SEC filings for Susan Blum.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions, including a significant grant of restricted stock units to the CFO, which is generally positive for aligning executive incentives. However, it lacks operational or financial performance data to significantly shift sentiment.

Positives

• The grant of 72,820 restricted stock units to a key executive like the CFO aligns her interests with shareholders and incentivizes long-term performance.
• The multi-year vesting schedule for the RSUs encourages executive retention and sustained contribution to the company's success.

Negatives

• The disposition of 9,767 shares, while for tax withholding, results in a slight reduction of the executive's direct equity ownership.

Risks

• The Power of Attorney explicitly states that the attorney-in-fact and CorMedix Inc. are not assuming Susan Blum's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended, highlighting her ongoing personal accountability for compliance.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction. It focuses solely on insider stock transactions and a power of attorney.

Industry Context

This filing, primarily an insider transaction report, does not provide information to analyze broader industry trends or competitor actions. It reflects standard executive compensation practices involving equity grants and subsequent tax-related share dispositions within the pharmaceutical or medical device industry, where CorMedix Inc. operates.

Comparison to Industry Standards

• This filing does not contain information that allows for a direct comparison of company results to global benchmarks or specific comparable companies/projects. It details an individual executive's stock transactions, which are common practice for executive compensation across industries.

Corporate Governance

Related Party Transactions

• Grant of 72,820 restricted stock units to Susan Blum, EVP and CFO, by CorMedix Inc.
• Disposition of 9,767 shares by Susan Blum for tax withholding related to the RSU vesting.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive aligns management's interests with shareholders, potentially fostering long-term value creation. The disposition for tax purposes is a routine event and has minimal impact.
• Management: The CFO's compensation package is enhanced through equity grants, incentivizing continued performance and retention.

Next Steps

• Susan Blum will continue to comply with Section 16(a) of the Securities Exchange Act of 1934 regarding her beneficial ownership.
• The granted restricted stock units will vest over a three-year period, subject to continued employment.

Key Dates

Recommendation

This filing is a routine insider transaction report and a power of attorney, not an operational or financial performance update. It provides no new information that would fundamentally alter the investment thesis for CorMedix Inc. The RSU grant is a standard compensation practice. Therefore, a "hold" recommendation is appropriate as there's no basis for a change in investment stance based solely on this document.

Keywords

CorMedix Inc., CRMD, Susan Blum, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Beneficial Ownership, SEC Filing, Power of Attorney, CFO